Latest Conference Articles

November 22nd 2025, 3:10am

Society for Neuro-Oncology Annual Meeting

Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.

November 22nd 2025, 2:24am

Society for Neuro-Oncology Annual Meeting

Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.

November 22nd 2025, 1:50am

Society for Neuro-Oncology Annual Meeting

The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.

November 22nd 2025, 1:31am

Society for Neuro-Oncology Annual Meeting

Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

November 20th 2025, 2:00pm

SITC Meeting

Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.

November 19th 2025, 1:04pm

PER® New York Lung Cancer Symposium

Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.

November 18th 2025, 9:04pm

PER® New York Lung Cancer Symposium

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

November 18th 2025, 3:00pm

PER® New York Lung Cancer Symposium

Alexander Drilon, MD, summarized approaches to TKI selection in NSCLC displaying oncogenic driver alterations for both TKI-pretreated and -naive patient populations.

November 17th 2025, 7:28pm

PER® New York Lung Cancer Symposium

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

November 16th 2025, 11:00am

PER® New York Lung Cancer Symposium

Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.

November 15th 2025, 10:25pm

PER® New York Lung Cancer Symposium

Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

November 15th 2025, 10:11pm

PER® New York Lung Cancer Symposium

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

November 15th 2025, 8:49pm

PER® New York Lung Cancer Symposium

Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.

November 15th 2025, 8:36pm

PER® New York Lung Cancer Symposium

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

November 15th 2025, 8:32pm

PER® New York Lung Cancer Symposium

Faiz Bhora, MD, FACS, discusses how data from the CheckMate 816, KEYNOTE-091, and AEGEAN trial have transformed perioperative therapy in resectable NSCLC.

November 9th 2025, 11:00am

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

October 30th 2025, 8:08pm

Bridging the Gaps in Lung Cancer

Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.

October 30th 2025, 8:06pm

Bridging the Gaps in Lung Cancer

Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.

October 30th 2025, 2:00pm

ESMO Congress: Lung Cancer

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

October 30th 2025, 12:00pm

ESMO Congress: GI Cancers

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.